This article first appeared on GuruFocus.
Novartis (NYSE:NVS), the Swiss pharmaceutical group, rebounded 0.8% to $138.545 Thursday as a major investor pushed for tougher boardroom oversight. Artisan Partners’ David Samra wants Novartis to strengthen its acquisition review process and establish a dedicated board committee to challenge major transactions before billions of dollars are committed.
The pressure arrived after two clinical disappointments helped trigger a record one-day stock plunge of more than 10%, wiping out nearly $30 billion in market value. Del-desiran, obtained through the $12 billion Avidity acquisition, missed its late-stage trial goal. Samra also questioned compensation measures that exclude writedowns, although he praised CEO Vas Narasimhan’s handling of the underlying business. Novartis stood by its guidance, pipeline and approach to capital allocation.
Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge · us.finance.gurufocus
The $12 billion Avidity purchase equals roughly 2.2 times Novartis’s latest quarterly free cash flow and about 83% of quarterly revenue. The picture adds a valuation warning: the $138.545 share price sits 5.81% above the $130.94 GF Value estimate. Other acquired drugs could still deliver returns, but the shareholder challenge cuts deeperwhether the board is skeptical enough before placing enormous bets on uncertain clinical assets.